Mounjaro Dosing Schedule: Starting Doses and Escalation Steps
Medically reviewed by Medical Advisory Board Last reviewed 2026-10-11
Labeled starting doses, four-week escalation rules, and administration guidelines from the FDA prescribing information
Per the FDA label, Mounjaro starts at 2.5 mg injected subcutaneously once weekly and increases in 2.5 mg steps after at least 4 weeks if additional glycemic control is needed. Adults reach a maximum of 15 mg weekly, while pediatric patients aged 10 and older have a 10 mg cap. Your prescriber sets the dose.
The labeled Mounjaro dosing schedule begins at 2.5 mg once weekly and increases in 2.5 mg increments after at least 4 weeks when additional glycemic control is needed. The FDA prescribing information sets these escalation rules to reduce gastrointestinal adverse reactions during treatment. Dose changes are determined by your prescriber rather than adjusted on your own.
Partner · Opt Health
Want medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →The Labeled Dosing Schedule
Mounjaro dosing begins at a starting dosage of 2.5 mg injected subcutaneously once weekly. If you need additional glycemic control, your prescriber can increase the dosage in 2.5 mg increments after at least 4 weeks on your current dose. The starting dosage and escalation schedule are followed to reduce the risk of gastrointestinal adverse reactions. You can track the labeled progression across the standard titration stages.
| Dose level | Weekly amount | Schedule requirement |
|---|---|---|
| Starting dose | 2.5 mg | At least 4 weeks |
| Intermediate steps | 5 mg to 12.5 mg | Minimum 4 weeks between increases |
| Adult maximum | 15 mg | Highest labeled weekly dose |
| Pediatric maximum | 10 mg | Ages 10 years and older |
Never accelerate this escalation timeline on your own.
Strengths and Available Presentations
Mounjaro comes in six distinct strengths to support the escalation schedule. Prefilled single-dose pens and single-dose vials are available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths. In addition to single-dose options, the multi-dose vial and the single-patient-use KwikPen each contain 4 doses.
Patients are informed which presentation they will receive and are trained on that specific device before starting. If your prescription switches to another format, your care team provides training on that new presentation. Patients using vials must use a syringe appropriate for dose administration, such as a syringe capable of measuring the prescribed dose, and must use a new syringe and needle for every injection.
Our Mounjaro cost guide covers pricing. You can read more in our breakdown of how tirzepatide works.
Missed Doses and Schedule Adjustments
If you miss a dose of Mounjaro, administer the injection as soon as possible within 4 days (96 hours) of the scheduled time. If more than 4 days have passed since your missed dose, skip that injection entirely. Take your next dose on your regularly scheduled injection day. To change the schedule safely, ensure that the time between two consecutive doses is at least 3 days (72 hours).
Administration Timing and Injection Sites
Mounjaro is administered subcutaneously once weekly at any time of day, with or without meals. Approved subcutaneous injection sites include the abdomen and the thigh. Another person can also administer the injection into the back of your upper arm. You must rotate your injection site with each weekly dose. Our overview of GLP-1 injection sites covers where injections go.
When taking Mounjaro alongside insulin, administer them as separate injections. Never mix insulin and Mounjaro. You may inject both products into the same body region, but the injection sites must not be directly adjacent to one another.
Adverse Reactions and Boxed Warning
Adverse reactions reported in 5% or more of patients include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. More detail is in our guide to GLP-1 side effects.
Mounjaro carries an FDA boxed warning regarding thyroid C-cell tumors. In animal studies, tirzepatide caused thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.
Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Approved Indications and Prescribing Boundaries
Mounjaro is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes. It is also approved to reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack, and non-fatal stroke, in adults with type 2 diabetes who are at high risk.
The label lists these type 2 diabetes uses. For weight management dosing, read our Zepbound dosing schedule and our Mounjaro vs Zepbound comparison for details.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.


Frequently Asked Questions
What is the starting dose of Mounjaro?
The recommended starting dosage of Mounjaro is 2.5 mg injected subcutaneously once weekly.
What is the maximum dose of Mounjaro?
The maximum dosage of Mounjaro is 15 mg once weekly in adults and 10 mg once weekly in pediatric patients aged 10 years and older. Your prescriber determines whether your treatment plan requires escalating toward that level.
How often can the Mounjaro dose be increased?
A prescriber can increase the Mounjaro dose in 2.5 mg increments after at least 4 weeks on the current dose. This gradual adjustment helps reduce gastrointestinal adverse reactions.
What if I miss a dose of Mounjaro?
Administer the missed dose as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and resume your regular injection schedule on your next scheduled day.
Which injection sites does the label list for Mounjaro?
The label specifies the abdomen and thigh for self-administration, or the back of the upper arm when injected by another person. Patients should rotate their injection site with each weekly dose.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Want weight loss handled by a physician who works from your labs? See how Opt Health does it →
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Guides
-
Mounjaro Weight Loss
Mounjaro (tirzepatide) for weight loss: mechanism, dose titration, expectations, and side effects.
-
Mounjaro Cost
Mounjaro cost without insurance: list price, savings card, coverage, and Medicare status.
-
Zepbound Dosing Schedule
Zepbound dosing schedule: the FDA titration steps and SURMOUNT trial dose-response data, without ranking a 'best' dose.
See more related guides
-
Saxenda vs Mounjaro: Obesity-approved Daily Shot vs Diabetes-branded Dual-action Drug Compared
Saxenda vs Mounjaro: obesity-approved daily shot vs diabetes-branded dual-action drug — approval pathway explained.
-
Foundayo vs Mounjaro: Obesity-approved Pill vs Diabetes-branded Dual-action Drug Compared
Foundayo vs Mounjaro: obesity-approved daily pill vs diabetes-branded dual-action drug — approval pathway explained.
-
Ozempic vs Mounjaro: Semaglutide vs Tirzepatide — Which GLP-1 Produces More Weight Loss?
Ozempic vs Mounjaro: semaglutide vs tirzepatide — mechanism, weight loss trials, and how to choose.
-
Wegovy vs Mounjaro: On-label Weight-loss Approval vs Off-label Diabetes Drug Compared
Wegovy vs Mounjaro: on-label weight-loss approval vs off-label diabetes drug compared.
-
Mounjaro vs Zepbound: Same Drug (Tirzepatide), Different Approval — Insurance and Access Explained
Mounjaro vs Zepbound: same drug (tirzepatide), different brand — insurance and access explained.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.